Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1500 of 3499 entries
View as:

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00499135 Org: User:
Start: 05/22/07 End: 05/14/14 Due: 05/14/15

A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00001683 Org: User:
Start: 10/31/97 End: 08/31/03 Due: 08/31/04

Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein

Phase: N/A Priority: Normal
NCT ID: NCT00048880 Org: User:
Start: 11/05/02 End: 07/02/08 Due: 07/02/09

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00245102 Org: User:
Start: 09/30/05 End: 03/31/11 Due: 03/31/12

High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01281176 Org: User:
Start: 02/09/11 End: 04/17/26 Due: 04/17/27

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Phase: N/A Priority: Normal
NCT ID: NCT03598244 Org: User:
Start: 11/27/18 End: 04/14/26 Due: 04/14/27

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01583686 Org: User:
Start: 05/04/12 End: 12/17/18 Due: 12/17/19

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Phase: N/A Priority: Normal
NCT ID: NCT01981525 Org: User:
Start: 01/27/14 End: 12/11/20 Due: 12/11/21

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00454571 Org: User:
Start: 06/30/06 End: 12/31/10 Due: 12/31/11

Capecitabine, Bevacizumab, and Radiation Therapy Followed By Gemcitabine and Bevacizumab in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00114179 Org: User:
Start: 01/31/05 End: 05/31/07 Due: 05/31/08

EF5 to Evaluate Tumor Hypoxia in Patients With High-Grade Soft Tissue Sarcoma or Mouth Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00896961 Org: User:
Start: 08/31/01 End: - Due: -

Imaging Study for FdCyd and THU Cancer Treatment

Phase: N/A Priority: Normal
NCT ID: NCT01479348 Org: User:
Start: 11/01/11 End: 01/11/19 Due: 01/11/20

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

Phase: N/A Priority: Normal
NCT ID: NCT04439266 Org: User:
Start: 08/12/15 End: 03/17/26 Due: 03/17/27

A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

Phase: N/A Priority: Normal
NCT ID: NCT01287104 Org: User:
Start: 01/29/11 End: 06/28/18 Due: 06/28/19

Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00058461 Org: User:
Start: 11/30/03 End: - Due: -

Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00049387 Org: User:
Start: 09/30/02 End: 06/30/07 Due: 06/30/08

EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02154399 Org: User:
Start: 05/31/02 End: 04/30/14 Due: 04/30/15

Radiation Therapy in Treating Patients With Glioblastoma

Phase: N/A Priority: Normal
NCT ID: NCT00019058 Org: User:
Start: 04/30/95 End: - Due: -

Voriconazole to Prevent Systemic Fungal Infections in Children

Phase: N/A Priority: Normal
NCT ID: NCT00005912 Org: User:
Start: 06/30/00 End: 01/31/01 Due: 01/31/02

Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT01856192 Org: User:
Start: 08/27/13 End: 12/31/25 Due: 12/31/26

Lenalidomide Maintenance Therapy for Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01675141 Org: User:
Start: 08/20/12 End: 03/10/17 Due: 03/10/18

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01989572 Org: User:
Start: 02/23/00 End: 01/31/13 Due: 01/31/14

Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00023712 Org: User:
Start: 11/05/01 End: 01/31/10 Due: 01/31/11

Study of Diets and Way of Life of Native Americans and Hispanics in New Mexico During the Time of the Trinity Nuclear Test

Phase: N/A Priority: Normal
NCT ID: NCT02211781 Org: User:
Start: 08/01/14 End: 05/21/18 Due: 05/21/19

Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme

Phase: N/A Priority: Normal
NCT ID: NCT01122888 Org: User:
Start: 12/31/09 End: 04/30/15 Due: 04/30/16